Regeneron Pharmaceuticals said that European officials recommended granting marketing authorization for its colorectal cancer treatment, Zaltrap. The injectable drug would be used to treat adults. The US Food and Drug Administration approved Zaltrap in August, and marketing authorization applications are under review with other agencies around the world, Regeneron said.
Regeneron Pharmaceuticals gets good marketing news
You've reached the limit of 10 free articles a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than $1 a week